Werewolf Therapeutics (HOWL) Prepaid Assets (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Prepaid Assets of $905000.0 for Q2 2026, down 68.17% year-over-year from $2.8 million in Q2 2025, and down 60.38% on a QoQ basis from $2.3 million in Q1 2026.
Werewolf Therapeutics (HOWL) Prepaid Assets (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Prepaid Assets for 7 years, with the latest figure at $905000.0 in Q2 2026.
- Prepaid Assets for Q2 2026 came in at $905000.0, down 68.17% year-over-year; the trailing twelve-month figure through Jun 2026 was $905000.0 (down 68.17% YoY), and the FY2025 annual result was $1.5 million, down 25.83% from the prior year.
- Prepaid Assets slipped to $905000.0 in Q2 2026, from $2.3 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $6.8 million in Q3 2022 and troughed at $905000.0 in Q2 2026.
- A 5-year average of $2.9 million and a median of $2.5 million in 2024 frame the typical range for Prepaid Assets.
- The widest annual swing landed in 2022, when Prepaid Assets surged 555.89%; it then tumbled 68.17% in 2026.
- A 5-year view of Prepaid Assets shows it stood at $4.0 million in 2022, then tumbled by 32.35% to $2.7 million in 2023, then slipped by 22.64% to $2.1 million in 2024, then retreated by 25.83% to $1.5 million in 2025, then tumbled by 41.08% to $905000.0 in 2026.
- Per Business Quant data, the three most recent Prepaid Assets figures were $905000.0 in Q2 2026, $2.3 million in Q1 2026, and $1.5 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 905,000.00 |
| Mar 31, 2026 | 2.28 Mn |
| Dec 31, 2025 | 1.54 Mn |
| Sep 30, 2025 | 2.46 Mn |
| Jun 30, 2025 | 2.84 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 2.07 Mn |
| Sep 30, 2024 | 2.54 Mn |
| Jun 30, 2024 | 2.94 Mn |
| Mar 31, 2024 | 2.32 Mn |
| Dec 31, 2023 | 2.68 Mn |
| Sep 30, 2023 | 3.29 Mn |
| Jun 30, 2023 | 3.02 Mn |
| Mar 31, 2023 | 2.44 Mn |
| Dec 31, 2022 | 3.96 Mn |
| Sep 30, 2022 | 6.84 Mn |
| Jun 30, 2022 | 6.23 Mn |
| Mar 31, 2022 | 1.73 Mn |
| Dec 31, 2021 | 3.54 Mn |
| Sep 30, 2021 | 3.97 Mn |